Samuel A Acquah
Examiner (ID: 1213)
Most Active Art Unit | 1711 |
Art Unit(s) | 2899, 1207, 1711, 1503, 1774, 1754 |
Total Applications | 2690 |
Issued Applications | 2329 |
Pending Applications | 91 |
Abandoned Applications | 269 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 17334688
[patent_doc_number] => 20220001019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => RANDOM CONJUGATE MOLECULE AND METHODS OF MAKING AND USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/839717
[patent_app_country] => US
[patent_app_date] => 2020-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27214
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16839717
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/839717 | RANDOM CONJUGATE MOLECULE AND METHODS OF MAKING AND USING THE SAME | Apr 2, 2020 | Abandoned |
Array
(
[id] => 16691668
[patent_doc_number] => 20210074147
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/828351
[patent_app_country] => US
[patent_app_date] => 2020-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69105
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828351
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/828351 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | Mar 23, 2020 | Abandoned |
Array
(
[id] => 16691668
[patent_doc_number] => 20210074147
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-11
[patent_title] => PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/828351
[patent_app_country] => US
[patent_app_date] => 2020-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69105
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828351
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/828351 | PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF | Mar 23, 2020 | Abandoned |
Array
(
[id] => 19505186
[patent_doc_number] => 12116598
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-15
[patent_title] => Thymic epithelial cells, exosomes derived therefrom, and methods of making and using same
[patent_app_type] => utility
[patent_app_number] => 16/823737
[patent_app_country] => US
[patent_app_date] => 2020-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 15
[patent_no_of_words] => 8704
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16823737
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/823737 | Thymic epithelial cells, exosomes derived therefrom, and methods of making and using same | Mar 18, 2020 | Issued |
Array
(
[id] => 16111663
[patent_doc_number] => 20200207854
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-02
[patent_title] => HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/800458
[patent_app_country] => US
[patent_app_date] => 2020-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28464
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16800458
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/800458 | HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES | Feb 24, 2020 | Abandoned |
Array
(
[id] => 16012839
[patent_doc_number] => 20200181262
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-11
[patent_title] => HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 16/800480
[patent_app_country] => US
[patent_app_date] => 2020-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28460
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16800480
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/800480 | HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES | Feb 24, 2020 | Abandoned |
Array
(
[id] => 15931195
[patent_doc_number] => 20200157231
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-21
[patent_title] => DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-LGR7 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 16/782728
[patent_app_country] => US
[patent_app_date] => 2020-02-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24920
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16782728
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/782728 | DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-LGR7 ANTIBODY | Feb 4, 2020 | Abandoned |
Array
(
[id] => 19551096
[patent_doc_number] => 12134795
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-05
[patent_title] => Sensor for cyanuric acid detection
[patent_app_type] => utility
[patent_app_number] => 16/750465
[patent_app_country] => US
[patent_app_date] => 2020-01-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 7241
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16750465
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/750465 | Sensor for cyanuric acid detection | Jan 22, 2020 | Issued |
Array
(
[id] => 15866233
[patent_doc_number] => 20200140520
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => IMMUNOSUPPRESSIVE TGF-B SIGNAL CONVERTER
[patent_app_type] => utility
[patent_app_number] => 16/743987
[patent_app_country] => US
[patent_app_date] => 2020-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15914
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16743987
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/743987 | IMMUNOSUPPRESSIVE TGF-B SIGNAL CONVERTER | Jan 14, 2020 | Pending |
Array
(
[id] => 16420527
[patent_doc_number] => 20200345725
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-05
[patent_title] => Methods and Compositions for Treating Cancer
[patent_app_type] => utility
[patent_app_number] => 16/740187
[patent_app_country] => US
[patent_app_date] => 2020-01-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 121097
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -67
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16740187
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/740187 | Methods and Compositions for Treating Cancer | Jan 9, 2020 | Abandoned |
Array
(
[id] => 19275489
[patent_doc_number] => 12025612
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-07-02
[patent_title] => Brown adipocyte progenitors in human skeletal muscle
[patent_app_type] => utility
[patent_app_number] => 16/713048
[patent_app_country] => US
[patent_app_date] => 2019-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 16
[patent_no_of_words] => 10156
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 94
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16713048
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/713048 | Brown adipocyte progenitors in human skeletal muscle | Dec 12, 2019 | Issued |
Array
(
[id] => 16837952
[patent_doc_number] => 20210145964
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => STROMA-TARGETING TREATMENT FOR PATIENTS WITH ELEVATED ADAM12 LEVELS
[patent_app_type] => utility
[patent_app_number] => 16/685100
[patent_app_country] => US
[patent_app_date] => 2019-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15399
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16685100
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/685100 | STROMA-TARGETING TREATMENT FOR PATIENTS WITH ELEVATED ADAM12 LEVELS | Nov 14, 2019 | Pending |
Array
(
[id] => 16087059
[patent_doc_number] => 20200197516
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => Antagonists of Products of the HS.459642 Unigene Cluster for the Inhibition of Proliferation, Development or Differentiation of Stem Cells Including Cancer Stem Cells
[patent_app_type] => utility
[patent_app_number] => 16/685279
[patent_app_country] => US
[patent_app_date] => 2019-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11537
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16685279
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/685279 | Antagonists of Products of the HS.459642 Unigene Cluster for the Inhibition of Proliferation, Development or Differentiation of Stem Cells Including Cancer Stem Cells | Nov 14, 2019 | Abandoned |
Array
(
[id] => 16091393
[patent_doc_number] => 20200199683
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => METHODS FOR EVALUATING AND TREATING WALDENSTROM'S MACROGLOBULINEMIA
[patent_app_type] => utility
[patent_app_number] => 16/684193
[patent_app_country] => US
[patent_app_date] => 2019-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19237
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684193
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/684193 | METHODS FOR EVALUATING AND TREATING WALDENSTROM'S MACROGLOBULINEMIA | Nov 13, 2019 | Abandoned |
Array
(
[id] => 15893501
[patent_doc_number] => 20200146269
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-14
[patent_title] => METHODS AND COMPOSITIONS FOR MODULATING INNATE LYMPHOID CELL PATHOGENIC EFFECTORS
[patent_app_type] => utility
[patent_app_number] => 16/681050
[patent_app_country] => US
[patent_app_date] => 2019-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51138
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16681050
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/681050 | METHODS AND COMPOSITIONS FOR MODULATING INNATE LYMPHOID CELL PATHOGENIC EFFECTORS | Nov 11, 2019 | Pending |
Array
(
[id] => 17385923
[patent_doc_number] => 20220033775
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => EXPANSION OF TILS UTILIZING AKT PATHWAYS INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 17/290639
[patent_app_country] => US
[patent_app_date] => 2019-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 146954
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290639
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/290639 | EXPANSION OF TILS UTILIZING AKT PATHWAYS INHIBITORS | Nov 3, 2019 | Pending |
Array
(
[id] => 17334562
[patent_doc_number] => 20220000893
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => METHOD FOR TREATING T-HELPER TYPE 2 MEDIATED DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/289413
[patent_app_country] => US
[patent_app_date] => 2019-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15184
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289413
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/289413 | METHOD FOR TREATING T-HELPER TYPE 2 MEDIATED DISEASE | Oct 29, 2019 | Pending |
Array
(
[id] => 15524819
[patent_doc_number] => 20200054715
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-20
[patent_title] => TREATMENT OF COLLAGEN DEFECTS USING PROTEIN SOLUTIONS
[patent_app_type] => utility
[patent_app_number] => 16/665975
[patent_app_country] => US
[patent_app_date] => 2019-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18144
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16665975
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/665975 | Treatment of collagen defects using protein solutions | Oct 27, 2019 | Issued |
Array
(
[id] => 16296349
[patent_doc_number] => 20200282072
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => ANTI-EGFR ANTIBODY DRUG CONJUGATE FORMULATIONS
[patent_app_type] => utility
[patent_app_number] => 16/655716
[patent_app_country] => US
[patent_app_date] => 2019-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34205
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16655716
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/655716 | ANTI-EGFR ANTIBODY DRUG CONJUGATE FORMULATIONS | Oct 16, 2019 | Abandoned |
Array
(
[id] => 15901177
[patent_doc_number] => 20200150107
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-14
[patent_title] => COMPOUNDS FOR TREATMENT OF DISEASES AND METHODS OF SCREENING THEREFOR
[patent_app_type] => utility
[patent_app_number] => 16/653874
[patent_app_country] => US
[patent_app_date] => 2019-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43758
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 85
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16653874
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/653874 | COMPOUNDS FOR TREATMENT OF DISEASES AND METHODS OF SCREENING THEREFOR | Oct 14, 2019 | Pending |